Core Viewpoint - Lexicon Pharmaceuticals has successfully closed a public offering of 32 million shares of common stock and a concurrent private placement of 22.4 million shares of common stock and 367,145 shares of Series B Convertible Preferred Stock, with the offerings closing on February 2, 2026 [1]. Group 1: Offering Details - The public offering price for the common stock was set at $1.30 per share, while the Series B Convertible Preferred Stock was sold at $65 per share [1]. - An additional 30-day option has been granted to underwriters to purchase up to 4.8 million shares of common stock at the public offering price [2]. - The Private Placement Purchaser has the option to buy an additional 94,855 shares of Series B Convertible Preferred Stock, convertible into 4,742,744 shares of common stock, at the same price of $65 per share [2]. Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offerings for the continued research and development of its drug candidates, as well as for working capital and other general corporate purposes [4]. Group 3: Regulatory Information - A shelf registration statement related to the public offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]. - The shares issued in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without proper registration or exemption [5]. Group 4: Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing medicines that transform patients' lives, with a pipeline targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolism, and other indications [7].

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy according to analysts. On January 14, Citi analyst Yigal Nochomovitz increased the price target for Lexicon to $2.10 from $1.90 while maintaining a Buy rating. This upward revision resulted from an updated financial model that accounted for upcoming milestones under the LX9851 partnership with Novo Nordisk. In Q3 2025, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) reported revenue of $14.2 million, which was drive ...

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be $41.6 ...

On January 14, Lale Akoner, global market analyst at eToro, appeared on CNBC to state that 2026 is driven by rotation into small caps and advised diversification. Recent data from BofA showed that customers had been selling equities over the six weeks leading up to that point, alongside observed outflows from ETFs that had previously seen consistent inflows. Akoner interpreted this not as a broad move away from risk assets, but rather as a significant rotation within the risk asset class. The shift is drive ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29, 2026 Lexicon Pharmaceuticals, Inc. Registrant's telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: | | Trading | Name of each exchange | | --- | --- | --- | | Title of each class | Symbol(s) | on which registered | | Common stock, par v ...

THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actua ...

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper unde ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Lexicon Pharmaceuticals has successfully completed the End-of-Phase 2 meeting with the FDA for pilavapadin, which is advancing into Phase 3 development for diabetic peripheral neuropathic pain (DPNP) [1][2] - The FDA raised no objections to the Phase 3 program, which will include two placebo-controlled studies comparing a 10 mg daily dose of pilavapadin to placebo [1][2] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to study nearly 5,000 genes and identify over 100 protein targets with therapeutic potential [4] - The company has a pipeline of drug candidates in various stages of development, targeting conditions such as neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, and metabolism [4] Product Information - Pilavapadin is a once-daily, orally delivered small molecule inhibitor of AAK1, designed to treat neuropathic pain without affecting opiate pathways [3] - Preclinical studies have shown that pilavapadin penetrates the central nervous system and reduces pain behavior in neuropathic pain models [3]

PresentationGood afternoon, everyone. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Alex Morrison. I'm an associate on JPM's health care team. Today, it's my pleasure to introduce Lexicon Pharmaceuticals. We'll have CEO, Mike Exton, speak; as well as Craig, Chief Medical Officer; and Scott, Chief Financial Officer, on stage for Q&A.Michael ExtonCEO & Director Great. So thanks so much, Alex, and thanks to JPMorgan for the invitation to present the Lexicon story. So for those of you wh ...